Onglyza Linked to Multiple Health Concerns
Onglyza is a drug used to treat high blood sugar levels in people with Type 2 Diabetes. It is popular because it doesn’t cause weight gain, like other medications, and is an effective blood sugar controller. Onglyza works by helping the pancreas to secrete more insulin, while stopping the liver from making excess sugar.
AstraZeneca and Bristol-Myers Squibb manufacture Onglyza, approved in 2009. It has been an incredibly successful drug, with predictions that annual sales could reach nearly $2.5 billion by 2018.
However, the success of the drug comes with a price. Patients who developed pancreatitis and/or pancreatic cancer after taking the drug have filed hundreds of lawsuits. The lawsuits allege that the drug maker did not properly warn of this dangerous side effect.
One study showed that people who take DPP-4 drugs like Onglyza show increased beta cells in the pancreas – which is good for people with Type 2 Diabetes because these cells help produce insulin – unfortunately the cells developed abnormally, causing complications.
In addition, the drug has been linked to an increased risk of heart failure. A 2013 study found an increased risk of heart failure in people taking the drug. People who are at risk for heart failure should likely avoid the drug, and the FDA requested in 2015 that the drug carry a warning of this life threatening side effect.
If you or a loved one has suffered dangerous side effects from taking Onglyza including pancreatic complications or heart failure, you could potentially take legal action against the drug maker for failure to warn of these complications. Contact a personal injury attorney at Roberts & Roberts to discuss the details of your situation.